Observational Study on the Clinical Use of ex Vivo Lung Perfusion (XPS™) for Lung Transplantation

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06795516

Acronym

EVLP XPS

Enrollment

Registered

2025-01-28

Start date

2025-03-01

Completion date

2026-03-03

Last updated

2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Transplantation

Keywords

Ex-vivo Perfusion

Brief summary

Clinical use of ex-vivo perfusion for lung transplantation. Collection, storage and processing of patient data for outcome analysis.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Min Age 18 years * Acceptance of the organ using the XPS™ ex vivo lung perfusion system is made by the center based on clinical assessment and visual inspection

Exclusion criteria

* The usual criteria for the assessment of donors apply * The transplanting surgeon is not satisfied with the lung assessment on the XPS™ according to clinical criteria

Design outcomes

Primary

Measure	Time frame
Survival of patients 1 year after transplantation	1 year after transplantation

Secondary

Measure	Time frame
Occurrence of primary graft dysfunction (PGD) after transplantation	0, 24, 48, 72 hours postTx

Countries

Germany

Contacts

PRINCIPAL_INVESTIGATORFabio Ius, Prof. Dr.

Hannover Medical School

Outcome results